Global Undescended Testicle Market is Segmented By Treatment Type (Hormone Therapy, Surgery and Others), By End User (Hospitals, Clinics and Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Market Size in USD Bn
CAGR7.3%
Study Period | 2023 - 2030 |
Base Year of Estimation | 2022 |
CAGR | 7.3% |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | High |
Major Players | Ferring Pharmaceuticals, Pfizer, Eli Lilly and Company, Sanofi, Merck & Co. and Among Others. |
The undescended testicle market size is expected to reach US$ 7.38 billion by 2030, from US$ 4.51 billion in 2023, at a CAGR of 7.3% during the forecast period. Undescended testicle, also known as cryptorchidism, is a condition in which one or both testicles fail to descend from the abdomen into the scrotum. The treatment options include hormone therapy and surgery. The rising prevalence of undescended testicles is driving market growth.
The global undescended testicle market is expected to witness steady growth due to rising incidences of undescended testis among newborn babies. Undescended testis, also known as cryptorchidism, is a congenital condition where one or both testes fail to descend into the scrotum. Left untreated, it can lead to infertility and testicular cancer. With growing awareness about the long-term effects of undescended testis and the availability of surgical procedures to treat it, the undescended testicle market is gaining traction globally. Furthermore, initiatives by governments and health organizations to screen newborns for this condition are supporting early diagnosis and treatment, driving market growth.
The undescended testicle market is segmented by treatment type, end-user, and region. By treatment type, the market is segmented into hormone therapy, surgery, and others. The hormone therapy segment accounts for the largest market share due to its high adoption rate as the first line of treatment. It is preferred due to its non-invasive nature.
Global Undescended Testicle Market Drivers:
Global Undescended Testicle Market Opportunities:
Global Undescended Testicle Market Restraints:
Analyst’s View on Global Undescended Testicle Market
The global undescended testicle market is expected to grow steadily over the forecast period. Factors such as increasing awareness about testicular cancer risks associated with undescended testicles and benefits of early corrective treatment will drive more people to seek medical help. Additionally, growing healthcare expenditures in developing nations will boost market opportunities. North America currently dominates the market and is expected to continue its leadership over the next five years. High awareness levels about men's health issues and easy availability of quality treatment options in the US and Canada are major factors supporting the region's large share. Europe is poised to be the second largest market owing to supportive public healthcare coverage and technological advancements in orchiopexy procedures. However, low consciousness, lack of health insurance, and socio-economic challenges in developing countries may negatively impact the overall industry expansion. High costs associated with surgeries also restrict the market potential in some regions. Looking forward, the market is likely to witness the fastest growth in Latin America and parts of Asia Pacific due to increasing healthcare spending, medical tourism, and rising per capita incomes in emerging nations. Improving access to care as a result of various government initiatives will provide new opportunities for market participants in these underpenetrated developing markets
Global Undescended Testicle Market Regional Insights:
Figure 1. Global Undescended Testicle Market Share (%), by Region, 2023
Major players operating in the global undescended testicle market include Ferring Pharmaceuticals, Pfizer, Eli Lilly, Sanofi, Merck & Co., Bayer, Endo International, AstraZeneca, Johnson & Johnson, Takeda Pharmaceutical
Global Undescended Testicle Market
New product launches:
Acquisition and partnerships:
Would you like to explore the option of buying individual sections of this report?
What are the key factors hampering growth of the undescended testicle market?
High cost of surgical procedures, side effects of hormone therapies, low awareness in developing regions, lack of healthcare infrastructure are the key factors hampering growth of the undescended testicle market
What are the major factors driving the undescended testicle market growth?
Increasing prevalence of undescended testicles, rising awareness about treatment, technological advancements, favorable reimbursement policies are the major factors driving the undescended testicle market growth
Which is the leading component segment in the undescended testicle market?
The hormone therapy segment accounts for the largest market share in the undescended testicle market due to its high adoption rate as the first line of treatment.
Which are the major players operating in the undescended testicle market?
Ferring Pharmaceuticals, Pfizer, Eli Lilly and Company, Sanofi, Merck & Co., Bayer AG, Endo International, AstraZeneca, Johnson & Johnson, Takeda Pharmaceutical
Which region will lead the undescended testicle market?
North America is expected to lead the undescended testicle market.
What will be the CAGR of undescended testicle market?
The CAGR of the undescended testicle market is expected to be 7.3% from 2023 to 2030.